immune system
• increased percentage of total B cells in the spleen compared with Faslpr homozygotes on a MRL background
|
• reduced percentage of lpr T cells in the spleen compared with Faslpr homozygotes on a MRL background
• increased percentage of total T cells in the spleen compared with Faslpr homozygotes on a MRL background
|
• compared with Faslpr homozygotes on a MRL background
|
• compared with Faslpr homozygotes on a MRL background
|
• less severe autoimmune disease (reduced spleen weight, reduced percentage of lpr T cells in the spleen, decreased nuclear autoantibodies, reduced glomeruli size, reduced grade of proteinuria and reduced immune complex deposition) compared with Faslpr homozygotes on a MRL background
• however, severity of renal disease is the same as in Faslpr homozygotes on a MRL background
|
• anti-double- and single-stranded autoantibodies compared with Faslpr homozygotes on a MRL background
|
• compared with Faslpr homozygotes on a MRL background
|
renal/urinary system
• reduced proteinuria compared with Faslpr homozygotes on a MRL background
|
• decreased size and immune complex deposition compared with Faslpr homozygotes on a MRL background
|
homeostasis/metabolism
• reduced proteinuria compared with Faslpr homozygotes on a MRL background
|
hematopoietic system
• increased percentage of total B cells in the spleen compared with Faslpr homozygotes on a MRL background
|
• reduced percentage of lpr T cells in the spleen compared with Faslpr homozygotes on a MRL background
• increased percentage of total T cells in the spleen compared with Faslpr homozygotes on a MRL background
|
• compared with Faslpr homozygotes on a MRL background
|
• compared with Faslpr homozygotes on a MRL background
|